Compare Stocks: SRPT, CTMX, EDIT, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.27 +1.9%	$3.45	$1.90 ▼ $8.21	$712.53M	2.12	4.83 million shs	623,100 shs
EDIT Editas Medicine	$3.08 -2.5%	$3.00	$1.66 ▼ $4.54	$473.03M	2.14	2.11 million shs	1.24 million shs
RYTM Rhythm Pharmaceuticals	$104.87 -2.1%	$109.78	$74.50 ▼ $122.20	$7.19B	1.92	765,707 shs	135,940 shs
SRPT Sarepta Therapeutics	$20.84 -0.1%	$17.73	$14.68 ▼ $25.32	$2.20B	0.23	3.07 million shs	480,050 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-2.13%	+3.55%	-6.96%	+57.35%
EDIT Editas Medicine	0.00%	+1.61%	+22.48%	-5.39%	+22.96%
RYTM Rhythm Pharmaceuticals	0.00%	-2.57%	+7.98%	+21.96%	+3.90%
SRPT Sarepta Therapeutics	0.00%	+11.02%	+40.38%	+18.46%	+14.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.27 +1.9%	$3.45	$1.90 ▼ $8.21	$712.53M	2.12	4.83 million shs	623,100 shs
EDIT Editas Medicine	$3.08 -2.5%	$3.00	$1.66 ▼ $4.54	$473.03M	2.14	2.11 million shs	1.24 million shs
RYTM Rhythm Pharmaceuticals	$104.87 -2.1%	$109.78	$74.50 ▼ $122.20	$7.19B	1.92	765,707 shs	135,940 shs
SRPT Sarepta Therapeutics	$20.84 -0.1%	$17.73	$14.68 ▼ $25.32	$2.20B	0.23	3.07 million shs	480,050 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-2.13%	+3.55%	-6.96%	+57.35%
EDIT Editas Medicine	0.00%	+1.61%	+22.48%	-5.39%	+22.96%
RYTM Rhythm Pharmaceuticals	0.00%	-2.57%	+7.98%	+21.96%	+3.90%
SRPT Sarepta Therapeutics	0.00%	+11.02%	+40.38%	+18.46%	+14.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	263.91% Upside
EDIT Editas Medicine	2.57	Moderate Buy	$5.50	78.57% Upside
RYTM Rhythm Pharmaceuticals	2.74	Moderate Buy	$141.12	34.56% Upside
SRPT Sarepta Therapeutics	2.20	Hold	$25.06	20.24% Upside

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/19/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/12/2026	SRPT Sarepta Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	CTMX CytomX Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00
8/5/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/5/2026	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$154.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$76.20M	9.35	N/A	N/A	$0.58 per share	5.64
EDIT Editas Medicine	$40.52M	11.67	N/A	N/A	$0.28 per share	11.00
RYTM Rhythm Pharmaceuticals	$189.76M	37.87	N/A	N/A	$2.08 per share	50.42
SRPT Sarepta Therapeutics	$1.97B	1.11	N/A	N/A	$10.89 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	11.33	0.31	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)

Latest SRPT, CTMX, EDIT, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
EDIT Editas Medicine	N/A	3.19	3.19
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EDIT Editas Medicine	71.90%
RYTM Rhythm Pharmaceuticals	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
EDIT Editas Medicine	3.10%
RYTM Rhythm Pharmaceuticals	5.90%
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	217.90 million	209.62 million	Optionable
EDIT Editas Medicine	230	153.58 million	148.82 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
SRPT Sarepta Therapeutics	1,372	105.63 million	98.34 million	Optionable

SRPT, CTMX, EDIT, and RYTM Headlines

Recent News About These Companies

Legal & General Group Plc Takes Position in Sarepta Therapeutics, Inc. $SRPT

August 31 at 4:56 AM | marketbeat.com

Man Group plc Takes $7.16 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 30 at 5:11 AM | marketbeat.com

Freestone Grove Partners LP Acquires Shares of 76,629 Sarepta Therapeutics, Inc. $SRPT

August 30 at 3:59 AM | marketbeat.com

Jefferies Financial Group Inc. Takes $3.42 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 29 at 6:02 AM | marketbeat.com

Deutsche Bank AG Takes $2.04 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 29 at 4:04 AM | marketbeat.com

Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution

August 28 at 7:35 AM | seekingalpha.com

OMERS ADMINISTRATION Corp Takes $864,000 Position in Sarepta Therapeutics, Inc. $SRPT

August 28 at 5:12 AM | marketbeat.com

SRPT Poised for Biggest Rally in 5 Months as Late-2026 Clinical Data Sparks Retail Investors’ ‘Monumental Comeback’

August 27, 2026 | profitconfidential.comP

SRPT on track for best week in 5 months ahead of late-2026 clinical data — retail eyes monumental comeback

August 27, 2026 | msn.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 15.2% - What's Next?

August 27, 2026 | marketbeat.com

Ieq Capital LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes $17.49 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

BlackRock Inc. Takes $341.34 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

August 24, 2026 | businesswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by Brokerages

August 24, 2026 | americanbankingnews.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of "Hold" by Brokerages

August 24, 2026 | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2% - Here's Why

August 19, 2026 | marketbeat.com

Sarepta Therapeutics Stock Short Interest Falls to 31.28%

August 18, 2026 | quiverquant.comQ

GSA Capital Partners LLP Purchases New Holdings in Sarepta Therapeutics, Inc. $SRPT

August 17, 2026 | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research

August 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SRPT, CTMX, EDIT, and RYTM Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$3.27 +0.06 (+1.87%)

As of 11:46 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$3.08 -0.08 (-2.53%)

As of 11:46 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Rhythm Pharmaceuticals NASDAQ:RYTM

$104.87 -2.30 (-2.15%)

As of 11:46 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Sarepta Therapeutics NASDAQ:SRPT

$20.84 -0.02 (-0.10%)

As of 11:46 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, CTMX, EDIT, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, CTMX, EDIT, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRPT, CTMX, EDIT, and RYTM Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Editas Medicine NASDAQ:EDIT

Rhythm Pharmaceuticals NASDAQ:RYTM

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, CTMX, EDIT, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, CTMX, EDIT, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRPT, CTMX, EDIT, and RYTM Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Editas Medicine NASDAQ:EDIT

Rhythm Pharmaceuticals NASDAQ:RYTM

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools